If you use semaglutide or tirzepatide and want to become pregnant, speak with the prescriber before changing the dose or trying to conceive. These medicines may improve weight and metabolism for some people, but they are not fertility treatments and should not be used during pregnancy. Planning must include the original indication, disease control, and how long the medicine remains in the body.

What GLP-1 medicines are

Semaglutide is a GLP-1 receptor agonist; tirzepatide acts on GIP and GLP-1 receptors. They reduce appetite and glucose and may cause weight loss. For someone with obesity or diabetes, managing these conditions can be part of preconception care. That does not show that the medicine increases fertility for everyone or that a regular cycle guarantees ovulation.

What fertility studies suggest

Recent literature describes signals of improved menstrual regularity, ovulation, and metabolic markers mainly in studies of polycystic ovary syndrome, often alongside other interventions. The review by Becker and colleagues summarizes emerging evidence, but also notes heterogeneous studies; reproductive outcomes do not make GLP-1 a universal fertility therapy [1]. A group result cannot predict one person’s chance.

Why stopping requires planning

The timing of discontinuation depends on the product and current regulatory guidance. Semaglutide remains in the body for a prolonged period; product information commonly advises stopping two months before a planned pregnancy. For tirzepatide, the interval depends on local labeling; UK product information advises at least one month before trying and attention to oral contraceptive effectiveness when starting or increasing the dose. Confirm current local labeling and medical advice [2].

Diabetes, weight, and other treatments

Stopping on your own may destabilize glucose, blood pressure, appetite, or mental health. Continuing without reviewing the plan is also inappropriate when pregnancy is possible. The plan may include metformin, insulin, nutrition changes, or another treatment, but the choice depends on the diagnosis. Do not replace prescribed care with supplements or an internet dose. Goldberg and Boots discuss obesity care and fertility in the era of GLP-1 receptor agonists [3].

When to seek care

  • Talk to a clinician before trying if you use semaglutide, tirzepatide, or another diabetes or weight medicine.
  • Seek earlier care for diabetes, very irregular cycles, absent periods, or PCOS.
  • Ask what to do if pregnancy occurs during treatment; do not rely on an internet test.
  • Assess both partners when conception is difficult.

How Levvi helps

Levvi lets you record cycles, flow, symptoms, medicines, reminders, sleep, and mood. For example, record the last dose and first period day to bring a timeline to an appointment and note changes after the plan your clinician sets. The app does not prescribe, calculate a safe washout period, or confirm ovulation or pregnancy.

Does the medicine increase fertility?

There is no basis for promising that semaglutide or tirzepatide increase fertility by themselves. In some people with obesity, diabetes, or PCOS, better metabolic control may coincide with more predictable cycles, but this is a complex clinical association. Available studies include small samples, different doses, and combinations with metformin. The safety review brings together preconception data and reinforces that pregnancy exposure should be avoided or promptly discussed with the care team [2].

How to organize a preconception visit

Make a list of the name, dose, last injection date, other medicines, and treatment goal. Also bring period dates, symptoms, hypoglycemia symptoms, weight, and conditions under care. Ask which alternative will keep the condition controlled, when it should begin, and which interval the team considers appropriate. If a pregnancy test is positive, contact the prescriber; do not change the dose alone.

Frequently asked questions

  • Can I become pregnant while using GLP-1? Yes, so contraception and planning should be discussed during treatment.
  • Is tirzepatide a PCOS treatment? There is no basis for turning it into a universal fertility treatment; indication is individual.
  • Does a regular cycle prove it worked? No. Regularity is one data point and does not confirm ovulation or pregnancy.
  • Can Levvi tell me when to stop? No. It organizes the timeline for a clinician’s decision.

Practical example: record Monday’s dose, Thursday’s period, a poor night of sleep, and the scheduled review in Levvi. In the appointment, that timeline helps separate perceived effects, normal cycle variation, and symptoms needing assessment. Tracking does not replace glucose testing, examination, ultrasound, or medication counseling.

Labeling and the interval before trying

The interval is not the same for every medicine. US Wegovy labeling advises stopping semaglutide at least two months before a planned pregnancy; UK Mounjaro information advises at least one month for tirzepatide, with additional contraception for four weeks after starting or increasing the dose. Local labeling and the clinical plan prevail.

Conclusion and clinical limits

A GLP-1 medicine may be part of metabolic care before pregnancy, but it should not be presented as a fertility enhancer. Semaglutide and tirzepatide require individualized review and planned discontinuation before conception. Available studies are recent, heterogeneous, and unable to answer every risk. The final decision is clinical and depends on the medicine, indication, health, and reproductive plan.